Project Grant R01CA301708
Award Date 5/15/26
Completion Date 4/30/31
Dollars Obligated $479K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90089, USA
Similar Awards
- Federal Grant Award Summary The University of Southern California received a $712,735 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2025, with a completion date of April 30, 2030. This award supports a Phase II randomized clinical trial investigating the synergistic therapeutic potential of SEPHB4-HSA, an ephrinB2 inhibitor, combined with pembrolizumab (PD-1 antibody) in muscle invasive bladder cancer (MIBC) patients....
- Federal Project Grant Award Summary The University of Southern California received a $451,259 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through June 30, 2029. This award supports fundamental research investigating heterochromatin repair mechanisms from a chromatin perspective. The project will deliver scientific discoveries addressing how chromatin...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded Columbia University's Health Sciences Division a $501,422 Project Grant effective May 1, 2026, through April 30, 2031, to advance research on synthetic lethal (SL) targeting in cancer. This research builds upon the institution's established expertise in identifying and characterizing SL drug targets and seeks to validate and mechanistically characterize the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Southern California a Project Grant totaling $650,450 under the Cancer Detection and Diagnosis Research program (CFDA 93.394), with performance extending from July 1, 2025 through June 30, 2030. This grant supports the development and translational advancement of IMT-423 (MHC-II-restricted CT83-specific CD4-dependent TCRM50A-STEM2 T cells), an innovative T cell receptor (TCR)-engineered CD4+ T cell...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $637,509 Project Grant to the University of California, San Diego (UCSD) on May 11, 2026, under the Cancer Biology Research program (CFDA 93.396) to support a five-year research initiative extending through April 30, 2031. This award funds fundamental research investigating how cancer cells achieve signaling autonomy—the ability to sustain growth in nutrient- and growth factor-deprived environments—through rewiring of...
- Federal Grant Award Summary The University of Southern California received a $162,501 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective May 1, 2026 through April 30, 2031. This T32 (institutional training) program delivers methodological training to six predoctoral trainees annually in advanced research approaches for social and behavioral cancer control and prevention. The training focuses on innovative study design,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded UC San Diego a $661,721 Project Grant effective April 1, 2026, through March 31, 2031, under the Cancer Biology Research program (CFDA 93.396). This award supports research focused on systematic functional mapping and interrogation of intrinsically disordered regions (IDRs) in oncogenic proteins. The project will deliver comprehensive domain and residue-level perturbation screening of IDRs across approximately...
- Federal Project Grant Award Summary The National Cancer Institute awarded the University of Southern California a $3,036,844 Project Grant on August 11, 2025, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and validate a wireless thermos-activator device for controllable solid tumor immunotherapy. The project addresses critical limitations in Chimeric Antigen Receptor (CAR) T cell therapy by creating a portable, patient-friendly alternative to MRI-guided...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of California, San Francisco a $680,597 Project Grant under the Cancer Biology Research program (CFDA 93.396) on April 1, 2026, with an anticipated completion date of March 31, 2031. This five-year award funds genome-wide in vivo CRISPR screening research designed to identify G-protein-coupled receptor (GPCR) pathway targets that enhance chimeric antigen receptor T (CAR-T) cell therapies...